Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Salient Pharma ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   7.4% 20.5% 23.9% 13.8% 14.5% 20.2% 16.0% 16.0%   Credit score (0-100)   34 6 3 15 14 5 12 12   Credit rating   BB B B BB BB B BB BB   Credit limit (kDKK)   0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -838 -730 -485 -261 -126 -233 0.0 0.0   EBITDA   -838 -1,327 -888 -261 -126 -233 0.0 0.0   EBIT   -838 -1,327 -888 -261 -126 -233 0.0 0.0   Pre-tax profit (PTP)   -910.5 -1,646.6 -901.6 -301.3 -188.2 -304.9 0.0 0.0   Net earnings   -710.2 -2,359.8 -901.6 -301.3 -188.2 -304.9 0.0 0.0   Pre-tax profit without non-rec. items   -910 -1,647 -902 -301 -188 -305 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   2,769 410 -492 -793 -981 -1,161 -1,343 -1,343   Interest-bearing liabilities   0.0 0.0 342 680 892 964 1,343 1,343   Balance sheet total (assets)   2,856 579 45.2 54.9 58.0 20.6 0.0 0.0   Net Debt   -2,073 -428 329 655 863 959 1,343 1,343     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -838 -730 -485 -261 -126 -233 0.0 0.0   Gross profit growth   19.8% 12.9% 33.6% 46.1% 52.0% -85.9% 0.0% 0.0%   Employees   0 1 1 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% -100.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   2,856 579 45 55 58 21 0 0   Balance sheet change%   347.6% -79.7% -92.2% 21.4% 5.7% -64.4% -100.0% 0.0%   Added value   -837.8 -1,326.6 -887.9 -261.3 -125.5 -233.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 -5.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   100.0% 181.8% 183.1% 100.0% 100.0% 100.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -32.1% -58.9% -159.1% -37.7% -13.3% -21.0% 0.0% 0.0%   ROI %   -38.6% -103.3% -236.3% -51.1% -16.0% -25.1% 0.0% 0.0%   ROE %   -41.7% -148.5% -396.4% -601.8% -333.3% -775.6% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   97.0% 70.8% -91.6% -93.5% -94.4% -98.3% -100.0% -100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   247.5% 32.3% -37.1% -250.7% -687.9% -411.0% 0.0% 0.0%   Gearing %   0.0% 0.0% -69.5% -85.7% -90.9% -83.0% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   9.3% 0.0% 8.0% 7.8% 8.0% 7.7% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   24.6 4.2 0.1 0.1 0.0 0.0 0.0 0.0   Current Ratio   24.6 4.2 0.1 0.1 0.1 0.0 0.0 0.0   Cash and cash equivalent   2,073.5 428.5 12.5 24.9 29.0 4.9 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   2,056.2 441.7 -491.9 -793.2 -981.4 -1,160.7 -671.7 -671.7   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 -1,327 -888 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 -1,327 -888 0 0 0 0 0   EBIT / employee   0 -1,327 -888 0 0 0 0 0   Net earnings / employee   0 -2,360 -902 0 0 0 0 0